OakChart

Sera Prognostics Inc

SERAHealthcare·Medical Devices·USA·Micro·NASD·Nov 11 • 3:59 PM ET

1.94-0.05 (-2.51%)
2026-11-11 22:15 CET
Market cap
79.14 USD m
Revenue, TTM
0.10 USD m
Net income, TTM
-33.47 USD m
Free cash flow, TTM
-28.99 USD m
EPS diluted, TTM
-0.66
P/E
-
Compare

Price

SERA against its 20, 50 and 200-day averages
2050200missearnings
1.502.002.50270K539KVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26SERAclose 1.9420-day 2.0450-day 2.04200-day 2.081.9452w low

49.6% under the 52-week high of 3.85 on 8 Jan 2026. 52-week low 1.56 on 14 May 2026. Last 15 sessions, 16.2% high to low

Volume 3.30× normal · the line is the 50-bar volume average

Profile

SERA
52-week range, 17% of the way up
1.563.85

Sera Prognostics, Inc. engages in the provision of personalized diagnostics to predict and manage pregnancy complications. It focuses on developing blood tests to predict the risks of preterm birth, preeclampsia and other pregnancy complications. The company was founded by Steven W. Graves, Dennis Farrar and M. Sean Esplin in 2008 and is headquartered in Salt Lake City, UT.

Employees72
IPOJul 15, 2021
Beta1.15
ATR, 14d0.11
Rel volume3.30
Short float0.75%
Insider own26.47%
Inst own40.14%

Snapshot

6 groups

Valuation

Index-
Market Cap77.15M
Enterprise Value36.33M
Income-33.47M
Sales0.10M
Book/sh1.32
Cash/sh1.11
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees72
IPOJul 15, 2021

Ratios

P/E-
Forward P/E-
PEG-
P/S771.52
P/B1.47
P/C1.75
P/FCF-
EV/EBITDA-
EV/Sales363.32
Quick Ratio1.88
Current Ratio1.88
Debt/Eq0.06
LT Debt/Eq0.06
Option/ShortYes / Yes

Earnings

EPS (ttm)-0.66
EPS next Y-0.57
EPS next Q-0.16
EPS this Y0.75%
EPS next Y13.53%
EPS next 5Y6.81%
EPS past 3/5Y22.30% -0.71%
Sales past 3/5Y-32.89% 26.51%
EPS Y/Y TTM13.67%
Sales Y/Y TTM1.05%
EPS Q/Q-0.51%
Sales Q/Q162.50%
EarningsNov 04 AMC
EPS/Sales Surpr.-14.29% -44.00%

Ownership

Insider Own26.47%
Insider Trans-0.79%
Inst Own40.14%
Inst Trans7.62%
ROA-35.59%
ROE-49.73%
ROIC-60.36%
Gross Margin-836.46%
Oper. Margin-38755.21%
Profit Margin-34866.67%
SMA20-4.89%
SMA50-5.02%
SMA200-6.61%
Trades-

Technical

Shs Outstand38.77M
Shs Float29.24M
Short Float0.75%
Short Ratio8.58
Short Interest0.22M
52W High3.85 -49.61%
52W Low1.56 24.36%
Volatility8.22% 3.78%
ATR (14)0.11
RSI (14)42.09
Beta1.15
Rel Volume3.30
Avg Volume25.62K
Volume84,544

Performance

Perf Week-3.72%
Perf Month-4.90%
Perf Quarter-3.48%
Perf Half Y22.01%
Perf YTD-34.24%
Perf Year-27.88%
Perf 3Y14.79%
Perf 5Y-82.28%
Perf 10Y-
Recom1.00
Target Price5.50
Prev Close1.99
Price1.94
Change %-2.51%

Analyst ratings

latest 5 of 5
DateActionAnalystRating changeTargetImplied
Jun 04, 2026InitiatedCCraig HallumBuy$6+209.3%
Dec 15, 2025InitiatedJJefferiesBuy$5+157.7%
Mar 30, 2022DowngradeCCitigroupBuy → Neutral$18 → $4+106.2%
Nov 19, 2021InitiatedOOppenheimerOutperform$19+879.4%
Oct 15, 2021ResumedCCowenOutperform

Peers

Mkt cap
TickerCompanyMkt cap
BDSXBiodesix Inc112.22M
NTRANatera Inc46.38B
LUCDLucid Diagnostics Inc77.52M
XGNExagen Inc121.98M
BLLNBilliontoone Inc5.27B
MYGNMyriad Genetics Inc548.68M
CSTLCastle Biosciences Inc1.05B
FEMYFemasys Inc12.57M
MDXHMDxHealth SA13.98M
VNRXVolitionRX Ltd5.67M

Insider trading

latest 14 of 95
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Inglis Tiffany Eul DavisChief Medical OfficerOct 12 '26Sale2.038,02416,28983,565Oct 13 05:06 PM
Inglis Tiffany Eul DavisOfficerOct 12 '26Proposed Sale2.038,02416,294Oct 13 05:04 PM
Anderson Dyaarl Lee Jr.Chief Commercial OfficerSep 10 '26Sale2.001,8003,60076,198Sep 11 04:07 PM
Lindgardt ZhenyaChief Executive OfficerSep 10 '26Sale2.007,02214,044837,848Sep 11 04:07 PM
Inglis Tiffany Eul DavisChief Medical OfficerSep 10 '26Sale2.0048697291,589Sep 11 04:07 PM
Jackson BenjaminGeneral CounselSep 10 '26Sale2.002,1904,380159,566Sep 11 04:07 PM
Lindgardt ZhenyaOfficerSep 10 '26Proposed Sale2.007,02214,045Sep 11 04:05 PM
Jackson BenjaminOfficerSep 10 '26Proposed Sale2.002,1904,380Sep 11 04:05 PM
Anderson Dyaarl Lee Jr.OfficerSep 10 '26Proposed Sale2.001,8003,600Sep 11 04:05 PM
Aerts AustinOfficerSep 10 '26Proposed Sale2.001,5093,018Sep 11 04:05 PM
Inglis Tiffany Eul DavisOfficerSep 10 '26Proposed Sale2.00486972Sep 11 04:05 PM
Lindgardt ZhenyaChief Executive OfficerSep 08 '26Sale2.0020,13940,278844,870Sep 09 04:07 PM
Lindgardt ZhenyaOfficerSep 08 '26Proposed Sale2.0020,13940,290Sep 09 04:05 PM
Aerts AustinOfficerSep 08 '26Proposed Sale2.0013,59127,195Sep 09 04:05 PM

Held by

AUM
TickerCompanyAUM
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
VXFVanguard Extended Market Index ETFAUM: 30.47B
IWCiShares Micro-Cap ETFAUM: 1.22B
BUSMEA Bridgeway Ultra-Small Company Market ETFAUM: 111.21M
DCORUS Core Equity 1 Portfolio ETF Class SharesAUM: 3.65B
AVSCAvantis U.S Small Cap Equity ETFAUM: 3.23B

News

latest 14 of 200
  • Sera Prognostics Misses On Revenue And EPS As A PreTRM Volume Surge Outruns Pricing (Earnings Whispers)
  • SERA PROGNOSTICS REPORTS THIRD QUARTER 2026 FINANCIAL RESULTS (PR Newswire)
  • Sera Prognostics Faces A Proof Test As Payer Momentum Meets Tiny Revenue Base (Earnings Whispers)
  • SERA PROGNOSTICS ANNOUNCES CONFERENCE CALL AND WEBCAST OF THIRD QUARTER FISCAL YEAR 2026 FINANCIAL RESULTS ON NOVEMBER 4, 2026 (PR Newswire)
  • 1 in 10 U.S. Babies Are Born Too Early. A Leading OB-GYN Says Most Mothers Can Learn Their Risk by Week 21, and Do Something About It. (PR Newswire)
  • SERA PROGNOSTICS APPOINTS SCOTT GLEASON CHIEF FINANCIAL OFFICER (PR Newswire) +5.53%
  • Sera Prognostics Inc (SERA) (Q2 2026) Earnings Call Highlights: Payer Momentum Builds with ... (GuruFocus.com)
  • SERA PROGNOSTICS REPORTS SECOND QUARTER 2026 FINANCIAL RESULTS (PR Newswire)
  • Earnings To Watch: Sera Prognostics Inc (SERA) Q2 2026 -- GF Value Sees 22% Downside (GuruFocus.com)
  • SERA PROGNOSTICS ANNOUNCES CONFERENCE CALL AND WEBCAST OF SECOND QUARTER FISCAL YEAR 2026 FINANCIAL RESULTS ON AUGUST 12, 2026 (PR Newswire)
  • PRIME SUBGROUP ANALYSIS DEMONSTRATES 22% REDUCTION IN NICU ADMISSIONS IN FIRST-TIME PREGNANCIES USING PreTRM Test-GUIDED CARE (PR Newswire)
  • SERA PROGNOSTICS ANNOUNCES APPOINTMENT OF MARK CAPONE TO ITS BOARD OF DIRECTORS (PR Newswire) +11.54%
  • SERA PROGNOSTICS COLLABORATES ON ARPA-H AWARD TO ADVANCE POINT-OF-CARE DIAGNOSTIC FOR SAFER BIRTH (PR Newswire)
  • SERA APPLAUDS ILLINOIS INITIATIVE TO EXPAND MEDICAID COVERAGE FOR PROTEOMIC BLOOD TESTING IN PREGNANCY (PR Newswire)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-11-04-0.160-0.140-0.1700.040.084
2026Q22026-08-12-0.180-0.154-0.1810.030.074
2026Q12026-05-06-0.170-0.167-0.1670.010.073
2025Q42026-03-18-0.160-0.189-0.1580.010.033
2025Q32025-11-13-0.160-0.198-0.1580.020.052
2025Q22025-08-06-0.160-0.225-0.1640.020.052
2025Q12025-05-07-0.200-0.235-0.1950.040.102
2024Q42025-03-19-0.250-0.240-0.2530.020.012
2024Q32024-11-06-0.240-0.219-0.2360.030.092
2024Q22024-08-07-0.250-0.264-0.2520.020.102
2024Q12024-05-08-0.250-0.272-0.2510.040.072
2023Q42024-03-20-0.250-0.258-0.2520.040.092
2023Q32023-11-08-0.230-0.336-0.2300.040.103
2023Q22023-08-09-0.340-0.357-0.3390.120.123
2023Q12023-05-10-0.340-0.380-0.3410.100.104
2022Q42023-03-22-0.310-0.359-0.3140.070.134

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2021FY-2.330-1.313-1.1380.080.19
2022FY-1.430-1.485-1.4280.270.36
2023FY-1.160-1.168-1.1620.310.34
2024FY-0.990-0.975-0.9920.080.11
2025FY-0.670-0.702-1.1600.080.10
2026FY--0.665--0.16
2027FY--0.575--1.80
2028FY--0.542--7.62
2029FY--0.430--12.10
2030FY--0.300--29.60

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q4S2026-11-054010.100.100.10
2026Q4S2026-11-044000.130.100.20
2026Q4S2026-10-274000.130.100.20
2026Q4S2026-08-134020.130.100.20
2026Q4S2026-07-214000.160.100.20
2026Q4S2026-06-244110.160.100.20
2026Q4S2026-06-034210.160.100.20
2026Q4S2026-05-073210.170.120.20
2026Q4S2026-04-103210.130.000.20
2026Q4S2026-03-193120.110.000.20
2026Q4S2026-02-133110.330.170.50
2026Q4S2026-02-123200.340.200.50
2026Q4S2026-01-073110.330.170.50
2026Q4S2026-01-063200.340.200.50

Estimate history

EPS, annual-0.538-0.647-1.138-1.428-1.162-0.992-0.67-0.6644
Period2019202020212022202320242025TTM
EPS, quarterly-0.236-0.253-0.195-0.164-0.158-0.158-0.167-0.181-0.159
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Sales, annual0.0360.0250.0820.2680.3060.0770.0810.1
Period2019202020212022202320242025TTM
Sales, quarterly0.0290.0240.0380.0170.0160.010.0140.030.042
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Shares, annual30.69930.69930.77431.01831.70434.17538.94539.741
Period2019202020212022202320242025MRQ
Shares, quarterly33.74334.17537.66438.02638.56938.94539.14439.43839.741
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY
Total Revenue0.100.080.080.310.270.080.030.04
Cost of Goods Sold Incl. D&A0.900.990.901.111.410.700.910.96
Gross Profit-0.80-0.91-0.82-0.80-1.14-0.61-0.88-0.93
Selling, General and Administrative Excl. Other36.4035.6035.8238.7244.5134.7817.0915.65
Research and Development11.7612.3513.9214.3214.2411.027.789.35
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-37.20-36.50-36.63-39.52-45.65-35.40-17.97-16.58
Interest Expense0.010.010.030.060.060.751.841.97
Unusual Expense0.000.000.000.300.00-1.030.08-1.97
Net Income Before Taxes-33.47-31.93-32.90-36.24-44.19-35.01-19.85-16.52
Income Taxes0.000.000.000.000.000.000.000.00
Consolidated Net Income-33.47-31.93-32.90-36.24-44.19-35.01-19.85-16.52
Net Income From Continuing Operations-33.47-31.93-32.90-36.24-44.19-35.01-19.85-16.52
Net Income-33.47-31.93-32.90-36.24-44.19-35.01-19.85-16.52
EPS (Recurring)-0.66-0.67-0.99-1.15-1.43-1.16-0.64-0.58
EPS (Basic, Before Extraordinaries)-0.66-0.67-0.99-1.16-1.43-1.14-0.65-0.54
EPS (Diluted)-0.66-0.67-0.99-1.16-1.43-1.14-0.65-0.54
EBITDA-36.38-35.56-35.80-38.62-44.43-34.74-17.08-15.63
Non-Operating Income (Expense)3.744.583.773.631.530.100.040.06
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense3.965.117.015.275.053.130.730.44
Price To Sales Ratio1,105.741,735.843,505.16609.74145.482,578.27--
Gross Margin-836.46-1,119.75-1,063.64-262.75-426.49-748.78-3,524.00-2,577.78
Operating Margin-38,755.21-45,066.67-47,577.92-12,915.36-17,034.33-43,164.63-71,884.00-46,044.44
Net Margin-34,866.67-39,417.28-42,724.68-11,843.79-16,487.31-42,693.90-79,392.00-45,891.67
Shares Outstanding39.7438.9434.1731.7031.0230.7730.7030.70
Market Capitalization79.1479.14274.91187.3939.08210.90214.89-

Income statement, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q22025Q12024Q4
Total Revenue0.040.030.010.010.020.020.040.02
Cost of Goods Sold Incl. D&A0.220.210.210.260.260.250.230.22
Gross Profit-0.18-0.18-0.19-0.25-0.24-0.23-0.19-0.20
Selling, General and Administrative Excl. Other8.719.829.178.718.749.099.069.22
Research and Development2.563.332.873.003.073.133.152.95
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-8.89-10.00-9.36-8.95-8.98-9.32-9.25-9.42
Interest Expense0.000.000.000.000.000.000.000.01
Unusual Expense0.000.000.000.000.000.000.000.00
Net Income Before Taxes-8.05-9.14-8.40-7.88-7.81-8.05-8.19-8.58
Income Taxes0.000.000.000.000.000.000.000.00
Consolidated Net Income-8.05-9.14-8.40-7.88-7.81-8.05-8.19-8.58
Net Income From Continuing Operations-8.05-9.14-8.40-7.88-7.81-8.05-8.19-8.58
Net Income-8.05-9.14-8.40-7.88-7.81-8.05-8.19-8.58
EPS (Recurring)-0.16-0.18-0.17-0.16-0.16-0.16-0.20-0.25
EPS (Basic, Before Extraordinaries)-0.16-0.18-0.17-0.16-0.16-0.16-0.20-0.25
EPS (Diluted)-0.16-0.18-0.17-0.16-0.16-0.16-0.20-0.25
EBITDA-8.70-9.81-9.17-8.71-8.74-9.08-9.03-9.21
Non-Operating Income (Expense)0.840.870.961.071.171.281.070.85
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense1.280.820.831.021.251.341.491.62
Price To Sales Ratio1,105.741,312.401,789.921,820.271,595.231,258.461,342.983,587.89
Gross Margin-433.33-606.67-1,371.43-2,470.00-1,493.75-1,364.71-497.37-833.33
Operating Margin-21,159.52-33,346.67-66,857.14-89,540.00-56,125.00-54,823.53-24,342.11-39,262.50
Net Margin-19,173.81-30,463.33-59,992.86-78,810.00-48,837.50-47,329.41-21,544.74-35,745.83
Shares Outstanding39.7439.4439.1438.9438.5738.0337.6634.17
Market Capitalization79.1471.2779.46113.85116.47104.35138.60274.91

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY
Cash & Short Term Investments39.2046.2449.0882.70105.1113.5321.39
Short Term Receivables0.010.0511.476.113.140.000.00
Inventories0.000.000.000.000.000.000.00
Other Current Assets1.561.310.801.311.990.200.16
Total Current Assets40.7747.6061.3490.12110.2513.7321.55
Net Property, Plant & Equipment3.551.853.183.061.770.961.64
Total Investments and Advances56.5821.9730.8421.3334.850.000.00
Intangible Assets0.911.03-----
Deferred Tax Assets0.620.17-----
Other Assets0.120.120.081.820.160.100.07
Total Assets102.5572.7595.44116.33147.0314.8023.26
Short Term Debt Incl. Current Port. of LT Debt0.000.841.020.980.078.103.74
Accounts Payable0.861.971.051.551.200.440.75
Other Current Liabilities23.3221.9622.3813.017.142.701.42
Total Current Liabilities24.1924.7724.4415.548.4111.245.90
Long Term Debt2.340.000.841.850.05128.51122.93
Provision for Risks Charges0.000.000.000.000.000.000.00
Deferred Tax Liabilities0.620.17-----
Other Liabilities0.000.000.000.000.000.611.05
Total Liabilities27.1424.9525.2817.398.46140.37129.88
Non-Equity Reserves0.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.00
Common Equity75.4147.8070.1698.94138.56-125.57-106.62
Total Shareholders Equity75.4147.8070.1698.94138.56-125.57-106.62
Accumulated Minority Interest0.000.000.000.000.000.000.00
Total Equity75.4147.8070.1698.94138.56-125.57-106.62
Total Liabilities & Stockholders Equity102.5572.7595.44116.33147.0314.8023.26
Book Value Per Share1.941.402.213.194.50-4.09-3.47
Tangible Book Value Per Share1.911.372.213.194.50-4.09-3.47
Full-Time Employees7264578911559-
Price to Book Ratio1.515.032.480.361.531.43-
Return on Assets-36.43-39.12-34.23-33.56-43.27-104.31-
Return on Equity-51.83-55.78-42.86-37.21-538.85--
Return on Invested Capital-41.07-68.82-51.05-43.84-25.26-674.87-101.34
Quick Ratio1.691.922.515.8013.111.223.65
Current Ratio1.691.922.515.8013.111.223.65

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY
Net Income-33.47-31.93-32.90-36.24-44.19-35.01-19.85-16.52
Depreciation0.820.940.830.901.220.660.900.95
Other Funds (Non Cash)4.515.916.604.634.812.762.40-0.10
Funds from Operations-28.14-25.08-25.46-30.71-38.16-31.59-16.56-15.68
Extraordinary Item0.000.000.000.000.000.000.000.00
Changes in Working Capital-0.36-0.5511.283.523.55-0.04-0.31-3.65
Cash from Operating Activities-28.50-25.62-14.19-27.19-34.61-31.64-16.87-19.32
Capital Expenditures-0.52-0.73-1.10-0.13-0.79-1.30-0.15-0.11
Net Assets From Acquisitions0.000.000.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.310.020.000.000.10
Purchase or Sale of Investments28.63-27.7812.840.266.33-81.250.000.00
Purchase of Investments-21.48-87.61-35.83-54.14-48.07-82.060.000.00
Sale Or Maturity of Investments50.1159.8448.6754.4054.400.800.000.00
Other Uses0.000.000.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.000.000.00
Cash from Investing Activities28.11-28.5011.740.445.55-82.56-0.15-0.01
Cash Dividends Paid0.000.000.000.000.000.000.000.00
Change in Capital Stock0.3054.223.051.220.31167.2610.8630.08
Repurchase of Common Pref Stock0.000.000.000.000.000.000.000.00
Sale of Common Pref Stock0.3054.223.051.220.31167.2610.8630.08
Proceedsfrom Stock Options0.0253.610.000.000.00165.5910.6929.15
Issuance or Reduction of Debt, Net-0.00-0.19-0.44-0.47-0.30-7.66-1.702.97
Change in Long Term Debt-0.00-0.19-0.44-0.47-0.30-7.66-1.702.97
Issuance of Long Term Debt0.000.000.000.000.000.001.056.59
Reduction of Long Term Debt-0.00-0.19-0.44-0.47-0.30-7.66-2.75-3.62
Net Financing Active Other Cash Flow0.000.000.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.000.000.00
Cash from Financing Activities0.3054.032.610.750.01159.599.1633.05
Net Change in Cash-0.10-0.100.16-26.00-29.0545.40-7.8613.72
Free Cash Flow-28.99-26.35-14.24-27.32-35.40-32.94-17.02-19.43
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.000.00
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Cash & Short Term Investments44.0946.4547.4039.2043.3040.16
Short Term Receivables0.020.010.010.010.010.02
Inventories0.000.000.000.000.000.00
Other Current Assets2.111.682.311.561.170.69
Total Current Assets46.2248.1349.7340.7744.4940.87
Net Property, Plant & Equipment3.983.733.453.553.491.52
Total Investments and Advances28.7433.8139.3756.5859.0868.35
Intangible Assets0.860.890.880.910.940.97
Deferred Tax Assets---0.62--
Other Assets0.170.170.120.120.120.12
Total Assets79.9886.7493.54102.55108.12111.83
Short Term Debt Incl. Current Port. of LT Debt0.260.000.000.000.000.35
Accounts Payable1.161.190.770.861.041.06
Other Current Liabilities23.1123.1722.6523.3222.4622.19
Total Current Liabilities24.5324.3623.4224.1923.5023.60
Long Term Debt3.023.002.502.342.440.00
Provision for Risks Charges0.000.000.000.000.000.00
Deferred Tax Liabilities---0.62--
Other Liabilities0.000.000.000.000.000.00
Total Liabilities27.5427.3625.9227.1425.9423.60
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity52.4459.3867.6275.4182.1888.23
Total Shareholders Equity52.4459.3867.6275.4182.1888.23
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity52.4459.3867.6275.4182.1888.23
Total Liabilities & Stockholders Equity79.9886.7493.54102.55108.12111.83
Book Value Per Share1.321.511.731.942.132.32
Tangible Book Value Per Share1.301.481.701.912.112.29
Full-Time Employees---72--
Price to Book Ratio1.511.051.051.381.321.10
Return on Assets-35.59-33.47-30.36-36.43-34.87-33.28
Return on Equity-49.73-45.03-39.58-51.83-47.69-44.24
Return on Invested Capital-14.52-14.65-11.98-10.14-9.23-9.12
Quick Ratio1.881.982.121.691.891.73
Current Ratio1.881.982.121.691.891.73

Cash flow, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Net Income-8.05-9.14-8.40-7.88-7.81-8.05
Depreciation0.190.190.190.240.240.24
Other Funds (Non Cash)1.191.100.891.331.411.52
Funds from Operations-6.67-7.84-7.31-6.31-6.16-6.29
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital-0.631.53-1.460.19-0.320.82
Cash from Operating Activities-7.30-6.31-8.77-6.12-6.48-5.47
Capital Expenditures-0.13-0.05-0.01-0.33-0.11-0.28
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments6.976.458.996.225.285.52
Purchase of Investments-2.03-10.66-1.01-7.78-7.97-15.30
Sale Or Maturity of Investments9.0017.1110.0014.0013.2520.82
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities6.846.398.985.895.175.24
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock0.050.140.020.090.390.08
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock0.050.140.020.090.390.08
Proceedsfrom Stock Options0.000.100.00-0.070.000.07
Issuance or Reduction of Debt, Net0.000.00-0.00-0.00-0.02-0.06
Change in Long Term Debt0.000.00-0.00-0.00-0.02-0.06
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.000.00-0.00-0.00-0.02-0.06
Net Financing Active Other Cash Flow0.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.00
Cash from Financing Activities0.050.140.020.090.370.02
Net Change in Cash-0.410.220.23-0.14-0.94-0.21
Free Cash Flow-7.43-6.33-8.78-6.45-6.59-5.75

Revenue breakdown

Services-Medical Laboratories2024: 77.00K 2025: 81.00K
United States2024: 77.00K 2025: 81.00K

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-300.75%0.2M29.2M23.12K
2026-10-150.77%0.2M29.0M25.37K
2026-09-300.79%0.2M29.0M29.56K
2026-09-150.74%0.2M29.0M33.48K
2026-08-310.77%0.2M28.9M37.29K
2026-08-140.78%0.2M29.0M49.43K
2026-07-310.80%0.2M28.8M54.54K
2026-07-150.84%0.2M28.8M51.13K
2026-06-300.91%0.3M29.0M50.29K
2026-06-150.92%0.3M29.0M58.45K
2026-05-291.01%0.3M29.4M68.93K
2026-05-150.96%0.3M29.4M58.65K
2026-04-301.02%0.3M29.4M51.08K
2026-04-151.29%0.3M27.0M58.29K
2026-03-311.41%0.4M27.1M62.48K
2026-03-130.91%0.2M27.1M59.55K
2026-02-271.06%0.3M26.7M49.04K
2026-02-131.08%0.3M26.7M49.22K
2026-01-301.18%0.3M26.7M51.49K
2026-01-151.26%0.3M26.7M51.07K

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call2.500.000.200.002.9850.000.000.392-0.0200.001
call5.000.000.100.004.5960.000.000.176-0.0200.001
call7.500.000.050.004.7220.000.000.092-0.0130.001
put2.500.100.650.002.1250.000.00-0.611-0.0200.001
put5.002.303.500.007.9830.000.00-0.824-0.0200.001
put7.504.806.000.009.3350.000.00-0.907-0.0140.001

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-0410-QQuarterly report pursuant to Section 13 or 15(d)2026-09-30SEC
2026-11-048-KCurrent report2026-11-04SEC
2026-10-134Statement of changes in beneficial ownership of securities2026-10-12SEC
2026-10-13144Filing for proposed sale of securities under Rule 144.SEC
2026-09-114Statement of changes in beneficial ownership of securities2026-09-10SEC
2026-09-11144Filing for proposed sale of securities under Rule 144.SEC
2026-09-114Statement of changes in beneficial ownership of securities2026-09-10SEC
2026-09-11144Filing for proposed sale of securities under Rule 144.SEC
2026-09-11144Filing for proposed sale of securities under Rule 144.SEC
2026-09-114Statement of changes in beneficial ownership of securities2026-09-10SEC
2026-09-11144Filing for proposed sale of securities under Rule 144.SEC
2026-09-114Statement of changes in beneficial ownership of securities2026-09-10SEC
2026-09-11144Filing for proposed sale of securities under Rule 144.SEC
2026-09-09144Filing for proposed sale of securities under Rule 144.SEC
2026-09-094Statement of changes in beneficial ownership of securities2026-09-08SEC
2026-09-09144Filing for proposed sale of securities under Rule 144.SEC
2026-09-024Statement of changes in beneficial ownership of securities2026-08-31SEC
2026-09-014Statement of changes in beneficial ownership of securities2026-08-31SEC
2026-09-013Initial statement of beneficial ownership of securities2026-08-31SEC
2026-08-198-KCurrent report2026-08-14SEC
2026-08-1210-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-128-KCurrent report2026-08-12SEC
2026-07-15SCHEDULE 13G/ASEC
2026-07-144Statement of changes in beneficial ownership of securities2026-07-10SEC
2026-07-144Statement of changes in beneficial ownership of securities2026-07-10SEC
2026-07-144Statement of changes in beneficial ownership of securities2026-07-10SEC
2026-07-144Statement of changes in beneficial ownership of securities2026-07-10SEC
2026-07-144Statement of changes in beneficial ownership of securities2026-07-10SEC
2026-07-144Statement of changes in beneficial ownership of securities2026-07-10SEC
2026-07-144Statement of changes in beneficial ownership of securities2026-07-10SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100016.29K1
2026-090063.27K5
2026-080000
2026-070000
2026-060090.62K8
2026-050000
2026-040000
2026-030099.17K14
2026-02004.68K1
2026-01005.94K1
2025-1200243.92K13
2025-1100135.28K9

Institutional holders

Manager% owned
BAKER BROS. ADVISORS LP14.04%
Whetstone Capital Advisors, LLC8.44%
Aberdeen Group plc7.49%
PSP Research LLC6.08%
Vivo Capital, LLC4.21%
VANGUARD CAPITAL MANAGEMENT LLC3.31%
CAPTRUST FINANCIAL ADVISORS1.37%
GEODE CAPITAL MANAGEMENT, LLC0.88%
SANDERS MORRIS HARRIS LLC0.80%
BlackRock, Inc.0.57%

Funds

Fund% owned
abrdn Healthcare Investors3.52%
abrdn Healthcare Opportunities Fund3.46%
VANGUARD TOTAL STOCK MARKET INDEX FUND2.27%
VANGUARD EXTENDED MARKET INDEX FUND0.97%
Fidelity Extended Market Index Fund0.41%
iShares Micro-Cap ETF0.26%
Ultra-Small Company Market Fund0.13%
Fidelity Total Market Index Fund0.13%
Fidelity Series Total Market Index Fund0.12%
Goldman Sachs Absolute Return Tracker Fund0.08%

OakChart. SERA. Cached 15 minutes.